Pharmacological interventions for people with borderline personality disorder (Q22252974)

7 February 2023

Clive E Adams

5

C E

Adams

1 reference

7 February 2023

Claire Binks

1

C A

Binks

1 reference

7 February 2023

Mark Fenton

series ordinal

2

author given names

M

author last names

Fenton

1 reference

7 February 2023

Lucy McCarthy

series ordinal

3

author given names

L

author last names

McCarthy

1 reference

7 February 2023

Tracey Lee

series ordinal

4

author given names

T

author last names

Lee

1 reference

Cochrane Database of Systematic Reviews

7 February 2023

language of work or name

English

0 references

publication date

25 January 2006

0 references

published in

0 references

issue

1

0 references

page(s)

CD005653

0 references

cites work

Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

The prevention of recurrent suicidal acts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

Paradoxical effects of amitriptyline on borderline patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

Efficacy of phenelzine and haloperidol in borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

Alprazolam-induced dyscontrol in borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

FACTOR ANALYSIS OF SOME PSYCHOMETRIC MEASURES OF IMPULSIVENESS AND ANXIETY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

An Inventory for Measuring Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

The Chestnut Lodge follow-up study. III. Long-term outcome of borderline personalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

A Structured Interview Guide for the Hamilton Depression Rating Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

The development and validation of the self-report test of impulse control

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

Issues in the meta-analysis of cluster randomized trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

The unit of analysis error in studies about physicians' patient care behavior

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

14-year follow-up of borderline and schizotypal personality disorders.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

Long-term follow-up of borderline patients in a general hospital.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

A trial of carbamazepine in borderline personality disorder.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

Interrelationship of Hysteroid Dysphoria and Borderline Personality Disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

Evidence of ten psychotic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

An inventory for assessing different kinds of hostility.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

A self-report Borderline Scale. Discriminative validity and preliminary norms.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

Behavioral treatments of suicidal behaviors. Definitional obfuscation and treatment outcomes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

Borderline personality organization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

An affective syndrome in psychopaths with borderline personality disorder?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

Low-Dose Clozapine in Acute and Continuation Treatment of Severe Borderline Personality Disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005653

7 January 2021

10.1002/14651858.CD005653

Identifiers

DOI

0 references

Fatcat ID

release_gvpkqps6vretbisotvho5pxul4

0 references